Showing results (171-180 of 213) with videos related to
Sort By:
Pageof 22
Pharmacoeconomics|September 17, 2008
Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?David R Rappange, Pieter H M van Baal, N Job A van Exel, et al.Journal of Affective Disorders|September 15, 2018
The cost-utility of stepped-care algorithms according to depression guideline recommendations - Results of a state-transition model analysisJolanda A C Meeuwissen, Talitha L Feenstra, Filip Smit, et al.European Journal of Public Health|January 5, 2019
Estimating disease prevalence from drug utilization data using the Random Forest algorithmLaurentius C J Slobbe, Koen Füssenich, Albert Wong, et al.International Journal of Chronic Obstructive Pulmonary Disease|November 16, 2017
Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sourcesMartine Hoogendoorn, Talitha L Feenstra, Melinde Boland, et al.European Journal of Pharmacology|August 6, 2011
Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular diseaseSimone R B M Eussen, Talitha L Feenstra, Ido B Toxopeus, et al.BMC Public Health|October 25, 2014
Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trialDenise A Peels, Rudolf R Hoogenveen, Talitha L Feenstra, et al.Diabetes, Obesity & Metabolism|December 30, 2020
Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohortsEva Pagano, Stefan R A Konings, Daniela Di Cuonzo, et al.European Journal of Clinical Investigation|January 16, 2007
Nasal nitric oxide in cystic fibrosis with and without hummingV M D Struben, W V Sewbalak, M H Wieringa, et al.Acta Diabetologica|April 21, 2022
The transferability and validity of a population-level simulation model for the economic evaluation of interventions in diabetes: the MICADO modelSajad Emamipour, Eva Pagano, Daniela Di Cuonzo, et al.Oncotarget|May 8, 2018
Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness studyRositsa G Koleva-Kolarova, Marcel J W Greuter, Talitha L Feenstra, et al.Pageof 22